Factors influencing nonleukemic death in refractory anemia, refractory anemia with ring sideroblasts, and refractory anemia with excess of blasts. 1987

S Oguma, and Y Yoshida, and H Uchino, and T Maekawa

The association between nonleukemic death and various features recorded at presentation in patients with refractory anemia (RA), RA with ring sideroblasts, and RA with excess of blasts was analyzed in 251 patients using the proportional hazards model. Features associated with higher nonleukemic death rates were: 1% or more metamyelocytes in peripheral blood (PB); lower 59Fe incorporation rate; 1% or more blasts in PB; lower hematocrit or hemoglobin; presence of giant platelets; 1 microgram/liter or higher serum vitamin B12 levels; higher periodic acid-Schiff positive erythroblasts; and 1% or higher promyelocytes in PB. Multivariate analysis was also performed using the following predictor variables: metamyelocytes in PB, micromegakaryocytes, hemoglobin, giant platelets, presence or absence of RA with excess of blasts, and mononuclear large megakaryocytes. Patients were divided arbitrarily into low (hazard ratio, less than 0.55), intermediate (hazard ratio, 0.55-1.5), and high (hazard ratio, greater than 1.5) risk groups. The cumulative nonleukemic death rates in the high and intermediate risk groups reached a median at 602 and 1984 days from presentation, respectively, while the rate reached a plateau level of 49.4% after 2644 days in the low risk group. The risk factors for leukemic transformation and nonleukemic death were found to be different and to need separate consideration.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000753 Anemia, Refractory A severe sometimes chronic anemia, usually macrocytic in type, that does not respond to ordinary antianemic therapy. Refractory Anemia,Anemias, Refractory,Refractory Anemias
D000754 Anemia, Refractory, with Excess of Blasts Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells. Leukemia, Smoldering,RAEB,RAEM,Refractory Anemia with Excess of Blasts,Leukemia, Smouldering,Leukemias, Smoldering,Smoldering Leukemia,Smoldering Leukemias,Smouldering Leukemia
D000756 Anemia, Sideroblastic Anemia characterized by the presence of erythroblasts containing excessive deposits of iron in the marrow. Anemias, Sideroblastic,Sideroblastic Anemia,Sideroblastic Anemias
D012306 Risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome. Relative Risk,Relative Risks,Risk, Relative,Risks,Risks, Relative

Related Publications

S Oguma, and Y Yoshida, and H Uchino, and T Maekawa
December 2013, Best practice & research. Clinical haematology,
S Oguma, and Y Yoshida, and H Uchino, and T Maekawa
December 1971, Schweizerische medizinische Wochenschrift,
S Oguma, and Y Yoshida, and H Uchino, and T Maekawa
March 2017, Blood research,
S Oguma, and Y Yoshida, and H Uchino, and T Maekawa
January 1998, Ryoikibetsu shokogun shirizu,
S Oguma, and Y Yoshida, and H Uchino, and T Maekawa
August 2002, American journal of hematology,
S Oguma, and Y Yoshida, and H Uchino, and T Maekawa
May 1983, Archives of pathology & laboratory medicine,
S Oguma, and Y Yoshida, and H Uchino, and T Maekawa
June 2015, American journal of hematology,
S Oguma, and Y Yoshida, and H Uchino, and T Maekawa
January 1992, Haematologica,
S Oguma, and Y Yoshida, and H Uchino, and T Maekawa
June 2011, Blood,
S Oguma, and Y Yoshida, and H Uchino, and T Maekawa
March 2010, The Korean journal of hematology,
Copied contents to your clipboard!